HER2/EGFR in Cancer Research

Alcohol Promotes ER+ Breast Cancer Cell Proliferation and Invasion Through the Upregulation of Neuregulin 1-Mediated ER-ErbB3 Crosstalk

This study shows alcohol promotes ER+ breast cancer cell proliferation and invasion by enhancing ER-ErbB3 signaling through NRG1 upregulation.

Spatial/molecular heterogeneity and treatment response in HER2+ early breast cancer: Translational analyses from the DAPHNe trial

The paper analyzes HER2+ breast cancer using multi-platform data to identify molecular predictors of response to neoadjuvant therapy and highlights intra-tumoral heterogeneity and immune exclusion mechanisms.

Impact of Trastuzumab and Pertuzumab on HER2 Localization and the Estrogen Receptor Cistrome in ER+/HER2+ Breast Cancer

This study examines how anti-HER2 therapy affects HER2 localization and ER genomic binding in ER+/HER2+ breast cancer, finding ER redistribution correlates with treatment resistance.

A CD109-SMURF2 Axis Diverts EGFR from Degradation to Sustain Oncogenic Signaling and Promote Squamous Cell Carcinoma Invasion and Stemness

This study identifies the CD109-SMURF2 axis as a mechanism that prevents EGFR degradation, sustaining oncogenic signaling and promoting SCC invasion and stemness.

Membrane PI(4,5)P2 and ErbB2 abundance regulate ErbB receptor oligomerization and kinase activation

This study shows that PI(4,5)P2 and ErbB2 levels regulate ErbB receptor oligomerization and kinase activity differently across family members.

TOPII-targeting and MUS81 deficiency sensitise HER2-low tumour models to T-DXd

This study identifies TopII targeting and MUS81 deficiency as sensitizers to T-DXd in HER2-low tumour models, showing increased cytotoxicity and DNA damage.

P95-HER2 promotes metastatic progression by biasing MRTFA dependent signaling

This study shows that the p95 isoform of HER2 promotes metastasis by biasing MRTFA-dependent signaling through specific tyrosine phosphorylation.

Rewiring of EGFR oncogenic program by opposing actions of membrane versus soluble CD109 in HNSCC

This study shows that soluble CD109 inhibits EGFR signaling and cancer stemness in HNSCC by blocking mCD109-EGFR interactions and promoting EGFR degradation.

Dual HER2/HER3 Targeting with Antibody-Drug Conjugates Reveals a Novel Therapeutic Strategy for HER2-Mutant Lobular Breast Cancer

This study shows HER2 mutations drive HER2/HER3 hyperactivation in ILC, making it sensitive to HER2/HER3-targeting ADCs, and highlights the synergy between T-DXd and P-DXd.

Loss of Flotillin-2 enhances trastuzumab emtansine internalization and cytotoxicity by relieving negative regulation of HER2 internalization in HER2-amplified cancers

This study shows that reducing Flotillin-2 increases T-DM1 internalization and cytotoxicity in HER2-amplified cancers by enhancing HER2 ubiquitination and internalization.

Hypoxia drives trastuzumab resistance through Rac1 pathway in HER2-positive breast cancer

This study identifies hypoxia-driven Rac1 pathway activation as a mechanism of trastuzumab resistance in HER2-positive breast cancer and shows Rac1 inhibition can restore drug sensitivity.

Epigenetic and 3D Genome Changes Drive Primary Trastuzumab Resistance in HER2+ Breast Cancer

This study identifies epigenetic and 3D genome changes as key drivers of primary trastuzumab resistance in HER2+ breast cancer through integrative analysis of chromatin architecture and histone modifications.

Proliferation and differentiation in intestinal organoids as a balance of ligand-modulated EGFR trafficking

This study shows that EGF and EREG ligands regulate proliferation and differentiation in mouse intestinal organoids by modulating EGFR endocytosis and surface expression.

Effects of N361 Glycosylation on Epidermal Growth Factor Receptor Biological Function

This study investigates how N361 glycosylation affects EGFR function, finding that the N361A mutation reduces proliferation and ligand sensitivity while increasing co-localization with HER2 and resistance to antibody inhibition.

Metabolic Alterations driven by PFKFB3 upregulation confer Resistance to Trastuzumab in HER2-Positive Breast Cancer.

This study identifies PFKFB3 upregulation as a driver of trastuzumab resistance in HER2+ breast cancer through metabolic rewiring and reduced ADCC, with clinical correlations to poor survival.

Recurrent cancer-associated ERBB4 mutations are transforming and confer resistance to targeted therapies

This study identifies recurrent ERBB4 mutations with oncogenic potential and resistance to targeted therapies, suggesting clinical implications for treatment strategies.

Soluble, but not precursor EGF induces intracrine signaling of the EGFR

The paper shows that soluble EGF (sEGF) induces intracrine EGFR signaling in the Golgi, while preEGF does not, and that this signaling is inhibited by erlotinib but not cetuximab.

Integrative proteo-genomic profiling uncovers key biomarkers of lapatinib resistance in HER2-positive breast cancer

The paper identifies a nine-marker signature of lapatinib resistance in HER2-positive breast cancer using integrative multi-omics analysis, revealing novel biomarkers and chromatin dynamics associated with drug resistance.

Quantification of HER2-low and ultra-low expression in breast cancer specimens by quantitative IHC and artificial intelligence

This paper develops qIHC and AI-based methods to quantify HER2 expression in breast cancer, showing significant differences between IHC categories and high spatial heterogeneity.

ECD co-operates with ERBB2 to promote tumorigenesis through upregulation of unfolded protein response and glycolysis

This study shows ECD and ERBB2 cooperate in breast cancer by enhancing unfolded protein response and glycolysis through direct mRNA binding and increased glucose uptake.

AGR2, a potential prognostic and predictive biomarker and therapeutic to overcome drug resistance in HER2-overexpressing cancer

This study identifies AGR2 as a prognostic biomarker and potential therapeutic target for overcoming drug resistance in HER2-overexpressing cancers.

HER2; p53 Co-mutated Cancers Show Increased Histone Acetylation and are Sensitive to Neratinib plus Trastuzumab Deruxtecan.

This study shows that HER2 and TP53 co-mutant cancers have increased histone acetylation and are sensitive to neratinib plus trastuzumab deruxtecan.

Grb7 is dispensable for Erbb2-driven mouse mammary tumorigenesis

This study shows that Grb7 is not required for Erbb2-driven mammary tumorigenesis in mice, as tumor development rates were similar between Grb7 knockout and proficient mice.

Micromapping (μMap) of HER2 Across Human Breast Cancers: Photocatalytic Proximity Labeling Identifies Primary Resistance Mechanisms and Functional Interactors

The paper uses photocatalytic proximity labeling to map HER2 interactions in breast cancer, identifying galectins and PTPRF as key players in resistance and signaling.

Site-Specific Immune and Stromal Architecture Drive Resistance to Trastuzumab Deruxtecan in HER2+ Metastatic Breast Cancer

This study identifies immune and stromal factors driving resistance to Trastuzumab Deruxtecan in HER2+ metastatic breast cancer using spatial proteomics.

Erbin interacts with NHERF1 and Ezrin to stabilize a membrane ErbB2 signaling complex in HER2-positive breast cancer

The paper shows Erbin interacts with NHERF1 and Ezrin to stabilize a membrane HER2 signaling complex in HER2-positive breast cancer, enhancing HER2 stability and transforming ability.

Thioredoxin reductase 3 inhibition sensitizes triple-negative breast cancer cells to EGFR inhibitors

This study identifies TXNRD3 as a target to sensitize triple-negative breast cancer cells to EGFR inhibitors by enhancing EGFR activation and surface localization.

Oxytocin receptor and HER2 interactions in breast cancer

This study investigates the interaction between the oxytocin receptor (OTR) and HER2 in HER2+ breast cancer, finding that OTR modulates HER2 signaling and response to therapy.

New Gain-of-Function Mutations Prioritize Mechanisms of HER2 Activation

The paper identifies new gain-of-function HER2 mutations using a high-throughput assay and links them to improved patient survival.

NOK promotes tumorigenesis through coordinating epidermal growth factor receptor to boost the downstream signaling in breast cancer

This study shows NOK promotes breast cancer by enhancing EGFR signaling through direct interaction and phosphorylation of downstream proteins like STAT3, STAT5, and Erk1/2.